Tech Company Financing Transactions
Intarcia Therapeutics Funding Round
On 12/31/2016, Intarcia Therapeutics raised $206 million in Series E investment from Bill & Melinda Gates Foundation and private investors.
Transaction Overview
Company Name
Announced On
12/31/2016
Transaction Type
Venture Equity
Amount
$206,000,000
Round
Series E
Investors
Bill & Melinda Gates Foundation (Sue Desmond-Hellmann)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Marina Park Dr. 13 Floor
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Website
Email Address
Overview
Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical company committed to developing innovative therapies that merge medicine with technology, and have the potential to transform therapeutic categories.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kurt Graves
Chief Scientific Officer
Andrew Young
VP - Client Services
Jay Smith
VP - General Counsel
Raymond Keane
VP - Human Resources
James Brady
VP - Manufacturing
Thomas Alessi
Browse more venture capital transactions:
Prev: 12/31/2016: Numetric venture capital transaction
Next: 12/31/2016: EquityZen venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs